JAK1/2 inhibitor ruxolitinib promotes the expansion and suppressive action of polymorphonuclear myeloid‐derived suppressor cells via the JAK/STAT and ROS‐MAPK/NF‐κB signalling pathways in acute graft‐versus‐host disease

Abstract

Objectives Ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor, demonstrates efficacy for treating steroid‐resistant acute graft‐versus‐host disease (SR‐aGVHD) following allogeneic stem cell transplantation (allo‐HSCT). Myeloid‐derived suppressor cells (MDSCs) have a protective effect on aGVHD via suppressing T cell function. However, the precise features and mechanism of JAK inhibitor‐mediated immune modulation on MDSCs subsets remain poorly understood. Methods A total of 74 SR‐aGVHD patients treated with allo‐HSCT and ruxolitinib were enrolled in the present study. The alterations of MDSC and regulatory T cell (Treg) populations were monitored during ruxolitinib treatment in responders and nonresponders. A mouse model of aGVHD was used to evaluate the immunosuppressive activity of MDSCs and related signalling pathways in response to ruxolitinib administration in vivo and in vitro . Results Patients with SR‐aGVHD who received ruxolitinib treatment achieved satisfactory outcomes. Elevation proportions of MDSCs before treatment, especially polymorphonuclear‐MDSCs (PMN‐MDSCs) were better to reflect the response to ruxolitinib than those in Tregs. In the mouse model of aGVHD, the administration of ruxolitinib resulted in the expansion and functional enhancement of PMN‐MDSCs and the effects could be partially reversed by an anti‐Gr‐1 antibody in vivo . Ruxolitinib treatment significantly elevated the suppressive function of PMN‐MDSCs through reactive oxygen species (ROS) production by Nox2 upregulation as well as bypassing the activated MAPK/NF‐κB signalling pathway. Additionally, ex vivo experiments demonstrated that ruxolitinib prevented the differentiation of mature myeloid cells and promoted the accumulation of MDSCs by inhibiting STAT5. Conclusions Ruxolitinib enhances PMN‐MDSCs functions through JAK/STAT and ROS‐MAPK/NF‐κB signalling pathways. Monitoring frequencies and functions of MDSCs can help evaluate treatment responses to ruxolitinib.

JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma

“…However, therapies rationally targeting myeloid cells remain in clinical development. JAKis target pathways directly involved in the suppressive programming of MDSCs ( 10 ); however, JAKis have been reported to promote ( 13 , 14 , 45 ) or restrain MDSC function or migration depending on the disease model ( 46 , 47 ). Moreover, JAKis exert direct effects on cancer cells ( 27 ), dendritic cells ( 48 ), NK cells ( 49 ), T cells ( 50 ), and other cell types ( 23 ), suggesting a context-dependent overall impact of therapeutic JAK inhibition.…”

Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy

“…However, its strong immunogenicity gave rise to pronounced hepatotoxicity and triggered a high-intensity cytokine storm when it went off-target, leading to its withdrawal from the market in 2017 35 . CRS is the predominant toxicity concern in therapies involving BsAbs that bridge T cells 36 . Existing pharmacological interventions, such as the immunosuppressant agent dexamethasone and the IL-6 receptor inhibitor tocilizumab, offer promising avenues for mitigating CRS.…”